Despite the surge in the number of biotech firms in developing countries hoping to meet the global demand for affordable drugs and vaccines, a study says that there is the danger of market forces pushing them to make more drugs for the rich.
University of Toronto researchers Rahim Rezaie and Peter Singer have come to this conclusion after studying 78 small, innovative biotech firms in India, China, Brazil and South Africa.
They found that companies in these developing nations have 69 affordable drugs and vaccines on the market, and another 54 in the pipeline, for local problems such as tuberculosis and tropical diseases.
Rezaie cites a company in India working with a Danish firm on a treatment for diabetes, and another in China working with US firms on drugs for inflammatory bowel disease. Both are diseases that are major problems only in the west.
Hyderabad-based Shantha Biotechnics, on the other hand, has made hepatitis B vaccination possible for millions of Indians by using bacteria equipped with viral genes to make the vaccine, slashing its cost by a factor of 60.
Last year, however, it was bought by Sanofi-Aventis, based in Paris, France, and there are fears its focus might change.
"These companies don't need to choose between global health and global wealth. There are things that can be done now to make it easier for them to make a profit and meet local needs as well," says Singer.
Such things include offering government or philanthropic money to entice companies in rich countries to focus on poor people's diseases, and getting drug companies to allow independent researchers to use their patents to develop drugs for neglected diseases, in return for a royalty payment.
"These [small biotech] companies are like a vein of gold that could be harnessed for global health. There's a brief window of opportunity now to make sure it's not tapped just to make necklaces for the rich," he adds.